| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Amplification is Associated with Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines and Primary Tumors
1 Department of Oncology, Lombardi Cancer Center, Washington, DC;
2 Department of Otolaryngology, Medstar-Georgetown University Hospital, Washington, DC; and
3 Institute for Molecular and Human Genetics, Lombardi Cancer Center, Washington, DC
Purpose: The purpose is to evaluate the association of glutathione S-transferase 
(GST-) amplification and cisplatin resistance in head and neck cancer.
Experimental Design: An analysis of chromosomal abnormalities in 10 head and neck cancer cell lines by comparative genomic hybridization was performed. GST- amplification and expression were evaluated in head and neck cell lines and paraffin-embedded tissue by fluorescence in situ hybridization (FISH) and immunohistochemistry.
Results: Changes in the DNA copy number were seen in all 10 cell lines by comparative genomic hybridization. The most frequent chromosomal alterations were: gain at 3q; loss at 3p; gain at 8q; loss of 18q; gain at 20q; loss at 8p; and gain of 11q11-q13. Using FISH, 9 of 10 cell lines showed increased GST- copy number. GST- amplification was detected in 7 of 10 cell lines. Five were relatively cisplatin resistant, and 2 were relatively cisplatin sensitive (mean IC50, 11.2 and 2.75 µM). Two relatively cisplatin-sensitive cell lines showed GST- gain and another relatively cisplatin-sensitive cell line had predominantly two copies of the gene. In 10 tumor specimens, 4 had two copies of GST-. All 4 had a complete response to neoadjuvant chemotherapy, 3 of whom are alive >50 months from treatment compared with 2 patients showing GST- amplification. Neither responded to chemotherapy, and both died of disease <9 months from diagnosis.
Conclusions: Using FISH, GST- amplification is a common event in head and neck squamous cell carcinoma and may be associated with cisplatin resistance and poor clinical outcomes in head and neck cancer patients treated with cisplatin-based therapy.
This article has been cited by other articles:
|
|
 |
|
  Y.-T. Liu, D. Shang, S. Akatsuka, H. Ohara, K. K. Dutta, K. Mizushima, Y. Naito, T. Yoshikawa, M. Izumiya, K. Abe, et al. Chronic Oxidative Stress Causes Amplification and Overexpression of ptprz1 Protein Tyrosine Phosphatase to Activate -Catenin Pathway Am. J. Pathol., December 1, 2007; 171(6): 1978 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Huang, L. Mills, and L. L. Worth Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells Mol. Cancer Ther., May 1, 2007; 6(5): 1610 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Wang and L. Y. W. Bourguignon Hyaluronan and the Interaction Between CD44 and Epidermal Growth Factor Receptor in Oncogenic Signaling and Chemotherapy Resistance in Head and Neck Cancer. Arch Otolaryngol Head Neck Surg, July 1, 2006; 132(7): 771 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Lecomte, B. Landi, P. Beaune, P. Laurent-Puig, and M.-A. Loriot Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy. Clin. Cancer Res., May 15, 2006; 12(10): 3050 - 3056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ruzzo, F. Graziano, K. Kawakami, G. Watanabe, D. Santini, V. Catalano, R. Bisonni, E. Canestrari, R. Ficarelli, E. T. Menichetti, et al. Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy J. Clin. Oncol., April 20, 2006; 24(12): 1883 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Wang and L. Y. W. Bourguignon Hyaluronan-CD44 Promotes Phospholipase C-Mediated Ca2+ Signaling and Cisplatin Resistance in Head and Neck Cancer Arch Otolaryngol Head Neck Surg, January 1, 2006; 132(1): 19 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Figueiredo, L. R. Cavalli, M. A. D. Pianovski, E. Lalli, R. Sandrini, R. C. Ribeiro, G. Zambetti, L. DeLacerda, G. A. Rodrigues, and B. R. Haddad Amplification of the Steroidogenic Factor 1 Gene in Childhood Adrenocortical Tumors J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 615 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Katahira, T. Takayama, K. Miyanishi, T. Hayashi, T. Ikeda, Y. Takahashi, R. Takimoto, T. Matsunaga, J. Kato, and Y. Niitsu Plasma Glutathione S-Transferase P1-1 as a Prognostic Factor in Patients with Advanced Non-Hodgkin's Lymphoma (Stages III and IV) Clin. Cancer Res., December 1, 2004; 10(23): 7934 - 7940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bae, S. Fan, Q. Meng, J. K. Rih, H. J. Kim, H. J. Kang, J. Xu, I. D. Goldberg, A. K. Jaiswal, and E. M. Rosen BRCA1 Induces Antioxidant Gene Expression and Resistance to Oxidative Stress Cancer Res., November 1, 2004; 64(21): 7893 - 7909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Henke, B. R. Haddad, S. E. Kim, J. D. Rone, A. Mani, J. M. Jessup, A. Wellstein, A. Maitra, and A. T. Riegel Overexpression of the Nuclear Receptor Coactivator AIB1 (SRC-3) during Progression of Pancreatic Adenocarcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6134 - 6142. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
